{"id":981582,"date":"2026-07-15T01:03:01","date_gmt":"2026-07-15T05:03:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/"},"modified":"2026-07-15T01:03:01","modified_gmt":"2026-07-15T05:03:01","slug":"molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/","title":{"rendered":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy<\/em><\/p>\n<\/li>\n<li>\n          <em>Presentation outlines Radio-DARPins\u2019 ability to match target and disease biology for improved outcomes<\/em><\/p>\n<\/li>\n<\/ul>\n<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July  15, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2W6R6KPh0aOxQLbD0OvgK4G_5fhtnAu20xnE5Pd5TkBhLdhzMygJDq6I_FvBhJkGr2K8ViF-8P6q1Sct9sUbPDS6j-HdZjExQZUnezDrky0=\" rel=\"nofollow\" target=\"_blank\">Molecular Partners<\/a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong>Appropriate Targets for RLT? High selectivity vs high expression<br \/><strong>Presenter:<\/strong>\u00a0Daniel Steiner, Ph.D.<br \/><strong>Time:\u00a0<\/strong>Wednesday July 15 at 11:10-11:30 ET<\/p>\n<p>The presentation outlines the ability of DARPins to match the biological characteristics of both the target and the disease, by optimizing their binding properties, systemic half-life, and biodistribution. To address tumor heterogeneity, Molecular Partners is also developing multispecific Radio-DARPins that can engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy.<\/p>\n<p>&#8220;Our multispecific Radio-DARPin approaches reflect Molecular Partners\u2019 ambition to push the boundaries of radiotheranostics and address the complexity and heterogeneity of cancer. By combining the versatility of DARPins with our deep expertise in designing multispecific medicines, we are exploring innovative approaches that have the potential to broaden patient reach and improve outcomes. This work represents an important step toward the next generation of radiopharmaceuticals,&#8221; said <strong>Daniel Steiner, Ph.D., SVP of Targeted Radio Therapeutics at Molecular Partners.<\/strong><\/p>\n<p>Building on the success of its first \u201cmono\u201d-targeting Radio-DARPins, the Company is highlighting the ability to expand its impact in the field of RLT through multispecific DARPins. These can be formatted either as a bispecific (two DARPins each binding an individual target) or as a 2-in-1 DuoDARPin (one DARPin able to bind two tumor targets in an either\/or manner).<\/p>\n<p>The Company\u2019s multispecific approaches enable the design of radiopharmaceuticals for effective treatment of highly heterogenous cancers, with target expression variability across tumor lesions and patients. Such bispecific radiopharmaceuticals could allow to treat cancer indications in which two targets are co-expressed solely on tumor tissues, creating tumor-specific solutions for patients with limited therapeutic options today.<\/p>\n<p>Molecular Partners\u2019 lead Radio-DARPin candidate MP0712, co-developed with Orano Med and targeting delta-like ligand 3 (DLL3), is in a multicenter US Phase 1\/2a trial, building on the successful generation of first imaging and dosimetry data from a compassionate care program. The second candidate MP0726, targeting mesothelin MSLN, is differentiated by its ability to selectively bind membrane-bound MSLN, and work towards first human imaging is expected this year. Molecular Partners expects to announce a third Radio-DARPin program, targeting a different tumor target, in 2026.<\/p>\n<p>Following today\u2019s presentation, a copy of the presentation from the Gordon Research Conference will be available on Molecular Partners website, under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0ijaRS3ZoAuXpGMjEn_BNdIhA1xhp8h8vzI2-3_QxN_5E2GKkWGfMeEOX0Nhvd5gXl5gOAbjuxq_Xz8Kpf12YPG-coW-R4esTe3jiIfkL6O0nbJSxivTh4KZYxvSvTMgT_5FoRwQVv3ySZ6DbXeACQ==\" rel=\"nofollow\" target=\"_blank\">Scientific Documents<\/a>.<\/p>\n<p>\n        <strong>About Gordon Research Conferences<\/strong><br \/>\n        <br \/>Founded in 1931, Gordon Research Conferences (GRC) is a nonprofit organization based in Rhode Island that organizes a series of internationally recognized scientific conferences across the biological, chemical, and physical sciences. GRC hosts hundreds of conferences annually, spanning fields from physics and neurobiology to materials science and medicine, and its meetings are known for fostering in-depth scientific discussion among leading researchers in each field. Attendance is limited and application-based, with participants selected by the conference chair, encouraging close interaction and community-building among scientists advancing the frontier of their fields.<\/p>\n<p>\n        <strong>About Radio-DARPins<\/strong><br \/>\n        <br \/>Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins\u2019 unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners\u2019 Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches, while preserving the advantages of the small protein format. Molecular Partners has established partnerships with industry leaders covering the full value chain for the development of its Radio-DARPin therapeutics, including a strategic collaboration with Orano Med \u2013 pioneer in the development of\u00a0<sup>212<\/sup>Pb-based targeted alpha therapies (TAT), a non-exclusive development agreement with Eckert &amp; Ziegler \u2013 global leader in radiopharmaceutical manufacturing, and a supply agreement with PanTera \u2013 a leading\u00a0<sup>225<\/sup>Ac radioisotope producer.<\/p>\n<p>\n        <strong>About Molecular Partners AG<\/strong>\u00a0<br \/>Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tYn_WtU82UgoDEip0HPAH3U82c3nCK5nU6D9umMufJwe5CDBstJzT3bmIxRmOr22ZCntP-79JuyqQ6-D5f3o2dNiGdzdUaTzChFU6TtJWljMguj2KznFmOasb_yvP4Nl\" rel=\"nofollow\" target=\"_blank\">www.molecularpartners.com<\/a> and find us on LinkedIn.<\/p>\n<p>\n        <strong>For further details, please contact:<\/strong><br \/>\n        <br \/>Seth Lewis, EVP Corporate Finance<br \/>Concord, Massachusetts, U.S.<br \/>seth.lewis@molecularpartners.com<br \/>Tel: +1 781 420 2361<\/p>\n<p>Laura Jeanbart, PhD, Head of Portfolio Management &amp; Communications <br \/>Zurich-Schlieren, Switzerland<br \/>laura.jeanbart@molecularpartners.com <br \/>Tel: +41 44 575 19 35<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners\u2019 current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners\u2019 product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners\u2019 collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners\u2019 expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as \u201caim\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cguidance\u201d, \u201cintend\u201d, \u201coutlook\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cwill\u201d and similar expressions, and are based on Molecular Partners\u2019 current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners\u2019 expectations include, but are not limited to, those set forth in under the heading \u201cRisk Factors\u201d in Molecular Partners\u2019 Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners\u2019 website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.<\/p>\n<p>Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmRkZGQxOTQtYzVhOS00OTA0LWEzYmQtZTBiOWVjZDliNGM3LTEyMTY1NDgtMjAyNi0wNy0xNS1lbg==\/tiny\/Molecular-Partners.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins\u2019 ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US. Title:\u00a0Appropriate Targets for RLT? High selectivity vs high expressionPresenter:\u00a0Daniel Steiner, Ph.D.Time:\u00a0Wednesday July 15 at 11:10-11:30 ET The presentation outlines the ability &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins\u2019 ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US. Title:\u00a0Appropriate Targets for RLT? High selectivity vs high expressionPresenter:\u00a0Daniel Steiner, Ph.D.Time:\u00a0Wednesday July 15 at 11:10-11:30 ET The presentation outlines the ability &hellip; Continue reading &quot;Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T05:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference\",\"datePublished\":\"2026-07-15T05:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/\"},\"wordCount\":1245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/\",\"name\":\"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\",\"datePublished\":\"2026-07-15T05:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/","og_locale":"en_US","og_type":"article","og_title":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk","og_description":"Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins\u2019 ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US. Title:\u00a0Appropriate Targets for RLT? High selectivity vs high expressionPresenter:\u00a0Daniel Steiner, Ph.D.Time:\u00a0Wednesday July 15 at 11:10-11:30 ET The presentation outlines the ability &hellip; Continue reading \"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-15T05:03:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference","datePublished":"2026-07-15T05:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/"},"wordCount":1245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/","name":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=","datePublished":"2026-07-15T05:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjIxMiM3NzA2MzA1IzIyMDQ5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}